Navigation Links
University of Vermont Health Network Ventures and Wilson Sonsini Goodrich & Rosati Invest in Biofactura, Inc.
Date:6/1/2019

The University of Vermont Health Network Ventures and legal firm Wilson Sonsini Goodrich & Rosati recently invested in BioFactura’s $6M Series B Financing Round.

“With the commitment from the UVM fund and WSGR, BioFactura is now securing value-added institutional investors who bring significant financial and business resources to bear as we advance our biopharmaceutical products to the clinic,” said Darryl Sampey, BioFactura’s President and CEO.

Dr. Jeffrey Hausfeld, Chairman of the Board and Chief Medical Officer, stated, “We are excited to work with the University of Vermont Health Network Ventures and WSGR and view them as important strategic investors in BioFactura. Both our Biosimilars and Biodefense drugs promote the health and safety of our patients using innovative, state of the art, biopharmaceutical manufacturing techniques. Improving access to highly effective biologic therapeutics, while bending the cost curve downwards in a meaningful way, are shared goals.”

Chris Jones, Director of Venture Investments for the UVM Health Network, commented, "Investments into biosimilars are directly aligned with the mission of improving access to care and reducing costs. There are additional benefits that BioFactura has revealed, such as improved quality and emergency preparedness, and I predict we will be seeing a lot of interest in this space and in this company going forward."

Charles Andres Ph.D., RAC, Associate Attorney specializing in Intellectual Property states, “WS Investments, the investment fund of Wilson, Sonsini, Goodrich & Rosati, was pleased to participate in the round.”

About BioFactura, Inc.
BioFactura, Inc. (Frederick MD) develops and commercializes high-value, highly similar biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFast™ Biomanufacturing Platform, the optimal system for bringing these drugs to market with faster, lower cost, superior-quality manufacture. For over 10 years, BioFactura has been advancing life-saving medicines from the research bench to the patient using its innovative drug development and manufacturing technologies. Current and past programs include biodefense drugs against smallpox and Ebola, novel medicines for cancer, and low-cost/high-quality biosimilars for autoimmune and infectious diseases. http://www.biofactura.com

About University of Vermont Health Network Ventures
University of Vermont Health Network Ventures is the highly selective, mission-led ventures arm of Vermont’s 6-hospital healthcare system. http://www.uvmhealth.org

About Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati is a law firm in the United States that specializes in business, securities, and intellectual property law. WSGR provides legal services to technology, life sciences, and growth enterprises worldwide, as well as the venture capital firms, private equity firms, and investment banks that finance them. The firm's clients operate in a range of technology industries, including the biotech, communications, digital media, energy, financial services, medical devices, mobile, semiconductor, and software sectors. http://www.wsgr.com

Read the full story at https://www.prweb.com/releases/university_of_vermont_health_network_ventures_and_wilson_sonsini_goodrich_rosati_invest_in_biofactura_inc/prweb16288101.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. uBiome Awards Grant to Stanford University to Study the Effect of Semen Microbiome on Fertilization and Embryo Development
2. Sensors Midwest Partners with Fraunhofer USA and Sonoma State University, CA, to host IoT Enabled Industry 4.0 Certification Workshop
3. Stephen Zarrilli Named President & CEO of University City Science Center
4. IBM Research and Cornell University to Use Genetic Sequencing and Big Data Analytics to Help Keep Global Milk Supply Safe
5. Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas
6. Temple University School of Medicine receives Grand Challenges Explorations grant
7. BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree
8. University of Delaware study connects penguin chick weights to local weather conditions
9. Johannes Gutenberg University Mainz joins Germanys Gauss-Allianz as a full member
10. The Genome Institute at Washington University Receives Irys System from BioNano Genomics to Advance Research for Genome Reference Consortium
11. University of Washington biotech start-up to develop game-changing cancer therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... ... November 12, 2019 , ... Atlantic ... purifiers, announced today that distributors voted their patented automatic and manual wipers the ... purifiers. , The most frequent maintenance task required of an ultraviolet water purifier ...
(Date:11/9/2019)... ... November 08, 2019 , ... SiteSeer Technologies, creator of SiteSeer Professional retail ... client and user of SiteSeer. The boutique real estate developer of single and multi-tenant ... SiteSeer to supplement its own analysis of markets. , Geoffrey Kerth, manager of ...
(Date:11/7/2019)... ... November 07, 2019 , ... R3 Stem Cell is now offering ... rest of 2019. The code to use during checkout is FIFTYOFF and applies to ... the nation’s leader in regenerative therapies with over 12,000 successful stem cell procedures performed ...
Breaking Biology News(10 mins):
(Date:10/22/2019)... ... October 22, 2019 , ... Enplug , ... Mass Notification System into its digital signage platform. The collaboration brings one of ... possible for users to leverage their existing digital signage networks to quickly disseminate ...
(Date:10/15/2019)... ... , ... ARPR , an award-winning tech PR agency at the epicenter of the future ... Agency of the Year in the Ragan’s Health Care PR & Marketing Awards. This award ... firm also revealed today that its healthIT practice group grew by 18 percent in Q3 ...
(Date:10/10/2019)... ... October 10, 2019 , ... VirTrial today ... centers in Europe. All Pratia research centers have completed VirTrial’s Virtual Trial Capable ... certified as Virtual Trial Capable and prepared to conduct decentralized clinical trials (DCT). ...
(Date:10/3/2019)... , ... October 01, 2019 , ... ... relax and reset itself, announced the midway point of its randomized research trial ... the study is to measure the efficacy of a non-invasive technology which compares ...
Breaking Biology Technology: